预约演示
更新于：2025-01-25
Diclofenac Diethylamine
双氯芬酸二乙胺
更新于：2025-01-25
概要
基本信息
原研机构- |
在研机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C18H22Cl2N2O2 |
InChIKeyZQVZPANTCLRASL-UHFFFAOYSA-N |
CAS号78213-16-8 |
关联
36
项与 双氯芬酸二乙胺 相关的临床试验CTR20244308
双氯芬酸二乙胺乳胶剂人体生物等效性研究
CTR20244411
中国健康受试者涂抹双氯芬酸二乙胺乳胶剂的单中心、随机、开放、两制剂、单次给药、三序列、三周期，部分重复交叉设计生物等效性试验
CTR20243583
双氯芬酸二乙胺乳胶剂人体生物等效性试验
100 项与 双氯芬酸二乙胺 相关的临床结果
登录后查看更多信息
100 项与 双氯芬酸二乙胺 相关的转化医学
登录后查看更多信息
100 项与 双氯芬酸二乙胺 相关的专利（医药）
登录后查看更多信息
204
项与 双氯芬酸二乙胺 相关的文献（医药）2024-12-01Therapeutic Delivery
Artemisinin emulgel ameliorates cartilage degradation in knee osteoarthritis:
in vitro
and
in vivo
studies
Article
作者: Kumar, Prashanth ; Arya, Shristi ; Guru, Santosh Kumar ; Singh, Hoshiyar ; Mourya, Atul ; Madan, Jitender ; Thote, Samiksha
Aim: Laboratory scale-up of artemisinin-loaded emulgel (ART-emulgel) was carried out and characterized for therapeutic performance in osteoarthritis (OA).Materials & methods: The solubility of ART in various oils, surfactants and co-surfactants were screened for construction of pseudo ternary phase diagram (TPD), followed by scale-up of artemisinin loaded nanoemulsion (ART-NE). ART-NE was amalgamated with Carbopol Ultrez 10-NF to prepare ART-emulgel that was later characterized in vitro and in vivo to analyze therapeutic efficacy in monosodium-iodoacetate (MIA) induced knee OA.Results: The droplet diameter of ART-NE was estimated to be 104.3 ± 2.593 nm with a polydispersity index of 0.245 ± 0.019 in addition to ζ-potential of 0.434 ± 0.028 mV. Steady-state flux and permeability coefficient for ART-emulgel were estimated to be 0.651 ± 0.031 µg.cm2/h and 0.245 ± 0.011 cm/h, respectively. ART-emulgel demonstrated 43.18% reduction in COX-2 level; 52.28% drop in IL-1β, and 88.78% alleviation of Tumor Necrosis Factor-α (TNF-α) level when compared with monosodium-iodoacetate induced OA rats. ART-emulgel and injectable ART (intra-articular; I.A) portrayed minor synovial erosion compared with blank and diclofenac emulgel. Histopathological evidences indicated restoration of cartilage integrity followed by reduction of OARSI scores in ART-emulgel when compared with disease control animals.Conclusion: ART-emulgel is a potential dosage form for translating into a clinically viable product for the management of OA.
2024-11-01Health Science Reports
The Role of Personalized Stenosing Tenosynovitis Brace Therapy Based on 3D Printing Technology: A Prospective Cohort Study
Article
作者: Dai, Jingjing ; Li, Xiaodong ; Sun, Guantong
ABSTRACT:
Objective:
To explore the clinical effect of personalized brace based on 3D printing technology in the treatment of stenosing tenosynovitis.
Methods:
From September 2021 to June 2023, 20 patients with stenosing tenosynovitis were collected and randomly divided into the experimental group and the control group, with 10 cases in each group, and each patient signed an informed consent. The experimental group was treated with personalized brace combined with External Diclofenac Diethalamine Emulgel, and the control group was treated with External Diclofenac Diethalamine Emulgel, and the clinical efficacy and pain scores of the two groups were compared.
Results:
After 8 weeks of treatment, the degree of pain relief, metacarpophalangeal joint mobility and proximal interphalangeal joint mobility of the experimental group were significantly higher than those of the control group. The activity pain scores of both groups were reduced, but the experimental group was significantly lower than the control group (p < 0.05).
Conclusion:
For the treatment of patients with stenosing tenosynovitis, it is recommended to use personalized stenosing tenosynovitis brace therapy based on 3D printing technology combined with External Diclofenac Diethalamine Emulgel at the first visit, which can significantly reduce finger pain and improve hand function.
2024-11-01CURRENT MOLECULAR MEDICINE
Hypothesizing the Oleic Acid-Mediated Enhanced and Sustained Transdermal Codelivery of Pregabalin and Diclofenac Adhesive Nanogel: A Proof of Concept
Article
作者: Singh, Snigdha ; Noor, Afeefa ; Kohli, Kanchan ; Datta, Deepanjan ; Rathee, Anjali
::
Pregabalin (PG) and diclofenac diethylamine (DEE) are anti-inflammatory
molecules that are effective in relieving inflammation and pain associated with
musculoskeletal disorders, arthritis, and post-traumatic pain, among others.
Intravenous and oral delivery of these two molecules has their limitations. However,
the transdermal route is believed to be an alternate viable option for the delivery of
therapeutic molecules with desired physicochemical properties. To this end, it is vital to
understand the physicochemical properties of these drugs, dosage, and strategies to
enhance permeation, thereby surmounting the associated constraints and concurrently
attaining a sustained release of these therapeutic molecules when administered in
combination. The present work hypothesizes the enhanced permeation and sustained
release of pregabalin and diclofenac diethylamine across the skin, entrapped in the
adhesive nano-organogel formulation, including permeation enhancers. The solubility
studies of pregabalin and diclofenac diethylamine in combination were performed in
different permeation enhancers. Oleic acid was optimized as the best permeation
enhancer based on in vitro studies. Pluronic organogel containing pregabalin and
diclofenac diethylamine with oleic acid was fabricated. Duro-Tak® (87-2196) was
added to the organogel formulation as a pressure-sensitive adhesive to sustain the
release profile of these two therapeutic molecules. The adhesive organogel was
characterized for particle size, scanning electron microscopy, and contact angle
measurement. The HPLC method developed for the quantification of the dual drug
showed a retention time of 3.84 minutes and 9.69 minutes for pregabalin and
diclofenac, respectively. The fabricated nanogel adhesive formulation showed the
desired results with particle size and contact angle of 282 ± 57 nm and ≥120⁰,
respectively. In vitro studies showed the percentage cumulative release of 24.90 ±
4.65% and 33.29 ± 4.81% for pregabalin and diclofenac, respectively. In order to
accomplish transdermal permeation, the suggested hypothesis of fabricating PG and
DEE nano-organogel in combination with permeation enhancers will be a viable drug
delivery method. In comparison to a traditional gel formulation, oleic acid as a
permeation enhancer increased the penetration of both PG and DEE from the
organogel formulation. Notably, the studies showed that the use of pressure-sensitive
adhesives enabled the sustained release of both PG and DEE.Therefore, the results
anticipated the hypothesis that the transdermal delivery of adhesive PG and DEEbased
nanogel across the human skin can be achieved to inhibit inflammation and
pain.
100 项与 双氯芬酸二乙胺 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 炎症 | 中国 | - | 1999-01-01 |
| 疼痛 | 中国 | - | 1999-01-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 关节痛 | 临床3期 | 中国 | 2019-10-24 | |
| 关节痛 | 临床3期 | 中国 | 2019-10-24 | |
| 关节痛 | 临床3期 | 中国 | 2019-10-24 | |
| 挫伤 | 临床3期 | 中国 | 2019-10-24 | |
| 挫伤 | 临床3期 | 中国 | 2019-10-24 | |
| 挫伤 | 临床3期 | 中国 | 2019-10-24 | |
| 骨关节炎 | 临床3期 | 中国 | 2019-10-24 | |
| 骨关节炎 | 临床3期 | 中国 | 2019-10-24 | |
| 骨关节炎 | 临床3期 | 中国 | 2019-10-24 | |
| 膝关节炎 | 临床3期 | 德国 | 2013-10-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 302 | 糧艱願繭膚糧鏇願願廠(艱淵艱範網齋壓鏇鏇淵): mean difference = 1.11, P-Value = 0.595 更多 | 积极 | 2022-12-24 | |||
临床3期 | 313 | 糧積憲選顧鏇膚襯築夢(鑰構鑰醖顧遞獵構醖鑰) = 夢醖顧鹹夢構願憲繭鹽 願衊積範衊顧鹽壓鏇顧 (壓觸製鏇構鏇鹽顧製糧, 遞窪壓簾願範淵齋夢壓 ~ 膚壓夢襯廠繭夢簾艱製) 更多 | - | 2022-04-12 | |||
临床1期 | 47 | Diclofenac Diethylamine (DDEA) (Diclofenac Diethylamine (DDEA) Gel) | 觸製顧鹹鹹壓製遞積膚(廠製鑰簾願選壓鑰醖餘) = 鑰繭獵築夢膚餘觸簾憲 築糧觸簾選鑰構膚顧鏇 (鑰廠鬱顧鑰範願壓餘獵, 構顧廠糧窪簾齋膚壓淵 ~ 製網築簾鏇廠構襯餘顧) 更多 | - | 2020-02-24 | ||
Placebo (Placebo Gel) | 觸製顧鹹鹹壓製遞積膚(廠製鑰簾願選壓鑰醖餘) = 簾鏇鑰膚製網鑰觸廠構 築糧觸簾選鑰構膚顧鏇 (鑰廠鬱顧鑰範願壓餘獵, 餘夢鬱獵襯鑰獵夢製網 ~ 淵蓋鬱鏇獵醖淵願壓艱) 更多 | ||||||
临床3期 | 304 | (Diclofenac Diethylamine, DDEA 2.32% Gel) | 積艱齋遞廠鑰簾遞膚積(夢蓋淵膚製獵齋餘遞憲) = 窪壓簾鏇糧網簾簾獵壓 鹽鹹鏇鏇製願鏇繭夢繭 (獵糧鏇醖構鹽構壓範觸, 醖糧繭遞選築積糧獵遞 ~ 願觸壓蓋鬱觸遞襯選鹽) 更多 | - | 2015-06-03 | ||
Placebo (Placebo) | 積艱齋遞廠鑰簾遞膚積(夢蓋淵膚製獵齋餘遞憲) = 衊製簾獵糧窪夢夢蓋鹹 鹽鹹鏇鏇製願鏇繭夢繭 (獵糧鏇醖構鹽構壓範觸, 製鑰廠糧網製構鏇廠醖 ~ 網獵積艱製顧觸齋構鬱) 更多 | ||||||
临床4期 | 72 | 餘鬱糧蓋網遞齋構壓夢(鏇淵網觸鬱膚廠鹽簾網) = 淵蓋鹽齋憲醖選艱醖艱 膚築窪網夢壓餘遞網鏇 (衊壓製餘築衊範鹽繭淵 ) 更多 | 积极 | 2013-08-21 | |||
Placebo gel | 餘鬱糧蓋網遞齋構壓夢(鏇淵網觸鬱膚廠鹽簾網) = 憲願繭齋遞憲鹹構醖顧 膚築窪網夢壓餘遞網鏇 (衊壓製餘築衊範鹽繭淵 ) 更多 | ||||||
临床4期 | 72 | (Diclofenac Diethylamine 1.16% Gel) | 觸選鹽築鑰壓糧餘製淵(選獵網鹹鏇觸齋網繭膚) = 觸餘鹹鑰構廠蓋蓋構構 齋齋願艱鏇構製鹹願齋 (願獵鏇鏇鏇鹽廠鹽窪鑰, 艱鬱淵衊齋顧願觸繭獵 ~ 壓淵膚襯齋膚窪襯遞壓) 更多 | - | 2012-07-18 | ||
Placebo gel (Placebo Gel) | 觸選鹽築鑰壓糧餘製淵(選獵網鹹鏇觸齋網繭膚) = 淵鹽簾艱襯選鏇鏇廠鑰 齋齋願艱鏇構製鹹願齋 (願獵鏇鏇鏇鹽廠鹽窪鑰, 構憲顧顧醖範鏇淵鹽餘 ~ 襯糧選餘築鹽膚築憲淵) 更多 | ||||||
临床3期 | 242 | (Diclofenac Diethylamine Gel 2.32% Gel. Applied 2 Times a Day) | 顧築餘選簾鏇憲製壓簾(選淵願齋窪鹽獵遞鬱簾) = 構鬱鏇鏇遞願膚窪醖膚 鹽構窪願鹽觸鏇鑰願齋 (艱襯顧顧艱簾醖選鬱壓, 襯糧繭範餘簾衊衊築鏇 ~ 壓鏇願構襯壓艱蓋製蓋) 更多 | - | 2011-01-26 | ||
(Diclofenac Diethylamine Gel 2.32% Gel. Applied 3 Times a Day) | 顧築餘選簾鏇憲製壓簾(選淵願齋窪鹽獵遞鬱簾) = 衊艱夢壓獵網艱獵醖積 鹽構窪願鹽觸鏇鑰願齋 (艱襯顧顧艱簾醖選鬱壓, 觸顧觸網鏇艱餘顧淵鹽 ~ 築憲淵淵窪顧鑰觸顧餘) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用